The prognostic impact of human leukocyte antigen (HLA) class I antigen abnormalities in salivary gland cancer. A clinicopathological study of 288 cases

Histopathology

Volumn 62, Issue 6, 2013, Pages 847-859

  Müller, Maximilian ^a   Agaimy, Abbas ^a   Zenk, Johannes ^a   Ettl, Tobias ^b   Iro, Heinrich ^a   Hartmann, Arndt ^a   Seliger, Barbara ^c   Schwarz, Stephan ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

HLA class I; Immune escape; Immunohistochemistry; Prognosis; Salivary gland cancer

Indexed keywords

BETA 2 MICROGLOBULIN; CALNEXIN; CALRETICULIN; ENDOPLASMIC RETICULUM P57; HEAVY CHAIN 10; HLA ANTIGEN CLASS 1; LOW MOLECULAR WEIGHT POLYPEPTIDE 2; LOW MOLECULAR WEIGHT POLYPEPTIDE 7; POLYPEPTIDE; TAPASIN; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER STAGING; DISTANT METASTASIS; DOWN REGULATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SALIVARY GLAND CARCINOMA; UPREGULATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGEN PRESENTATION; ATP-BINDING CASSETTE TRANSPORTERS; BETA 2-MICROGLOBULIN; CALNEXIN; CHILD; CYSTEINE ENDOPEPTIDASES; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA-A ANTIGENS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; PROTEASOME ENDOPEPTIDASE COMPLEX; SALIVARY GLAND NEOPLASMS; TISSUE ARRAY ANALYSIS; YOUNG ADULT;

EID: 84876794226     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12086     Document Type: Article

References (51)

1. Risk M, Corman JM. The role of immunotherapy in prostate cancer: an overview of current approaches in development. Rev. Urol. 2009; 11; 16-27.
2. Rao B, Han M, Wang L et al. Clinical outcomes of active specific immunotherapy in advanced colorectal cancer and suspected minimal residual colorectal cancer: a meta-analysis and system review. J. Transl. Med. 2011; 9; 17.
3. Speetjens FM, Zeestraten EC, Kuppen PJ, Melief CJ, van der Burg SH. Colorectal cancer vaccines in clinical trials. Expert Rev. Vaccines 2011; 10; 899-921.
4. Genetzakis M, Gomatos IP, Georgiou AN et al. BCL-2, p53 and HLA-DR antigen expression in surgically treated parotid cancer patients. Eur. Arch. Otorhinolaryngol. 2009; 266; 417-424.
5. Hamano H, Haneji N, Yanagi K, Ishimaru N, Hayashi Y. Expression of HLA-DR and cytokine genes on interferon-gamma-stimulated human salivary gland cell line. Pathobiology 1996; 64; 255-261.
6. Ogawa Y, Hong SS, Toyosawa S, Chang CK, Yagi T. Expression of major histocompatibility complex class II antigens and interleukin-1 by epithelial cells of Warthin's tumor. Cancer 1990; 66; 2111-2117.
7. Thrane PS, Sollid LM, Brandtzaeg P. Abundant dendritic cells express HLA-DR in pleomorphic adenomas. Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 1990; 59; 195-203.
8. Garrido F, Ruiz-Cabello F, Cabrera T et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol. Today 1997; 18; 89-95.
9. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol. 2000; 74; 181-273.
10. Seliger B, Maeurer MJ, Ferrone S. Antigen-processing machinery breakdown and tumor growth. Immunol. Today 2000; 21; 455-464.
11. Seliger B. Different regulation of MHC class I antigen processing components in human tumors. J. Immunotoxicol. 2008; 5; 361-367.
12. Barnes L, Eveson JW, Reichart P, Sidransky D eds. Pathology and Genetics of Head and Neck Tumours. World Health Organization Classification of Tumours. Lyon: IARC Press, 2005; 430.
13. Sobin LH, Gospodarowicz MK, Wittekind C, International Union against Cancer. TNM Classification of Malignant Tumours, 7th ed. Chichester: Wiley-Blackwell, 2010.
14. Jouzdani E, Yachouh J, Costes V et al. Prognostic value of a three-grade classification in primary epithelial parotid carcinoma: result of a histological review from a 20-year experience of total parotidectomy with neck dissection in a single institution. Eur. J. Cancer 2010; 46; 323-331.
15. Therkildsen MH, Christensen M, Andersen LJ, Schiodt T, Hansen HS. Salivary gland carcinomas-prognostic factors. Acta Oncol. 1998; 37; 701-713.
16. Goode RK, El-Naggar AK. Mucoepidermoid carcinoma. In Barnes L, Eveson JW, Reichart P, Sidransky D eds. Pathology and Genetics of Head and Neck Tumours. World Health Organization Classification of Tumours. Lyon: IARC Press, 2005; 219-220.
17. Elston EW, Ellis IO. Method for grading breast cancer. J. Clin. Pathol. 1993; 46; 189-190.
18. Milanes-Yearsley M, Hammond ME, Pajak TF et al. Tissue micro-array: a cost and time-effective method for correlative studies by regional and national cancer study groups. Mod. Pathol. 2002; 15; 1366-1373.
19. Ettl T, Stiegler C, Zeitler K, et al. EGFR, HER2, survivin, and loss of pSTAT3 characterize high-grade malignancy in salivary gland cancer with impact on prognosis. Hum. Pathol. 2012; 43; 921-931.
20. Stam NJ, Spits H, Ploegh HL. Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J. Immunol. 1986; 137; 2299-2306.
21. Perosa F, Luccarelli G, Prete M, Favoino E, Ferrone S, Dammacco F. Beta 2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide. J. Immunol. 2003; 171; 1918-1926.
22. Lampson LA, Fisher CA, Whelan JP. Striking paucity of HLA-A, B, C and beta 2-microglobulin on human neuroblastoma cell lines. J Immunol 1983; 130; 2471-2478.
23. Bandoh N, Ogino T, Cho HS et al. Development and characterization of human constitutive proteasome and immunoproteasome subunit-specific monoclonal antibodies. Tissue Antigens 2005; 66; 185-194.
24. Wang X, Campoli M, Cho HS et al. A method to generate antigen-specific mAb capable of staining formalin-fixed, paraffin-embedded tissue sections. J. Immunol. Methods 2005; 299; 139-151.
25. Ogino T, Wang X, Kato S, Miyokawa N, Harabuchi Y, Ferrone S. Endoplasmic reticulum chaperone-specific monoclonal antibodies for flow cytometry and immunohistochemical staining. Tissue Antigens 2003; 62; 385-393.
26. Temponi M, Kageshita T, Perosa F, Ono R, Okada H, Ferrone S. Purification of murine IgG monoclonal antibodies by precipitation with caprylic acid: comparison with other methods of purification. Hybridoma 1989; 8; 85-95.
27. Ettl T, Baader K, Stiegler C, et al. Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer. Br. J. Cancer 2012; 106; 719-726.
28. Mehta AM, Jordanova ES, Kenter GG, Ferrone S, Fleuren GJ. Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. Cancer Immunol. Immunother. 2008; 57; 197-206.
29. Leffers N, Gooden MJ, Mokhova AA et al. Down-regulation of proteasomal subunit MB1 is an independent predictor of improved survival in ovarian cancer. Gynecol. Oncol. 2009; 113; 256-263.
30. van Endert PM. Genes regulating MHC class I processing of antigen. Curr. Opin. Immunol. 1999; 11; 82-88.
31. Chapman DC, Williams DB. ER quality control in the biogenesis of MHC class I molecules. Semin. Cell Dev. Biol. 2010; 21; 512-519.
32. Vitale M, Rezzani R, Rodella L et al. HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions. Cancer Res. 1998; 58; 737-742.
33. Murray PG, Constandinou CM, Crocker J, Young LS, Ambinder RF. Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin's disease. Blood 1998; 92; 2477-2483.
34. Kageshita T, Hirai S, Ono T, Hicklin DJ, Ferrone S. Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am. J. Pathol. 1999; 154; 745-754.
35. Seliger B, Stoehr R, Handke D et al. Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer. Cancer Immunol. Immunother. 2009; 59; 529-540.
36. Meissner M, Reichert TE, Kunkel M et al. Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin. Cancer Res. 2005; 11; 2552-2560.
37. Vigneron N, Peaper DR, Leonhardt RM, Cresswell P. Functional significance of tapasin membrane association and disulfide linkage to ERp57 in MHC class I presentation. Eur. J. Immunol. 2009; 39; 2371-2376.
38. Atkins D, Ferrone S, Schmahl GE, Storkel S, Seliger B. Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma? J. Urol. 2004; 171; 885-889.
39. Cathro HP, Smolkin ME, Theodorescu D, Jo VY, Ferrone S, Frierson HF Jr. Relationship between HLA class I antigen processing machinery component expression and the clinicopathologic characteristics of bladder carcinomas. Cancer Immunol. Immunother. 2010; 59; 465-472.
40. Ogino T, Bandoh N, Hayashi T, Miyokawa N, Harabuchi Y, Ferrone S. Association of tapasin and HLA class I antigen down-regulation in primary maxillary sinus squamous cell carcinoma lesions with reduced survival of patients. Clin. Cancer Res. 2003; 9; 4043-4051.
41. Bijen CB, Bantema-Joppe EJ, de Jong RA et al. The prognostic role of classical and nonclassical MHC class I expression in endometrial cancer. Int. J. Cancer 2010; 126; 1417-1427.
42. Seliger B, Ritz U, Abele R et al. Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res. 2001; 61; 8647-8650.
43. Atkins D, Breuckmann A, Schmahl GE et al. MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma. Int. J. Cancer 2004; 109; 265-273.
44. Benevolo M, Mottolese M, Piperno G et al. HLA-A, -B, -C expression in colon carcinoma mimics that of the normal colonic mucosa and is prognostically relevant. Am. J. Surg. Pathol. 2007; 31; 76-84.
45. Menon AG, Morreau H, Tollenaar RA et al. Down-regulation of HLA-A expression correlates with a better prognosis in colorectal cancer patients. Lab. Invest. 2002; 82; 1725-1733.
46. Tanaka K, Tsuchikawa T, Miyamoto M et al. Down-regulation of human leukocyte antigen class I heavy chain in tumors cancer patients. Int. J. Oncol. 2011; 40; 965-974.
47. Huang WC, Wu D, Xie Z et al. Beta2-microglobulin is a signaling and growth-promoting factor for human prostate cancer bone metastasis. Cancer Res. 2006; 66; 9108-9116.
48. Schwarz S, Zenk J, Muller M et al. The many faces of acinic cell carcinomas of the salivary glands: a study of 40 cases relating histological and immunohistological subtypes to clinical parameters and prognosis. Histopathology 2012; 61; 395-408.
49. Frentzel S, Kuhn-Hartmann I, Gernold M, Gott P, Seelig A, Kloetzel PM. The major-histocompatibility-complex-encoded beta-type proteasome subunits LMP2 and LMP7. Evidence that LMP2 and LMP7 are synthesized as proproteins and that cellular levels of both mRNA and LMP-containing 20S proteasomes are differentially regulated. Eur. J. Biochem. 1993; 216; 119-126.
50. Rock KL, Goldberg AL. Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu. Rev. Immunol. 1999; 17; 739-779.
51. Brooks P, Fuertes G, Murray RZ et al. Subcellular localization of proteasomes and their regulatory complexes in mammalian cells. Biochem. J. 2000; 346(Pt 1); 155-161.